TP53 and cancer: CarR-OVCAR3 rather exhibited significantly reduced viability and elevated apoptotic rates when treated with a combination of carboplatin and APR-246 [25, 26], a small molecule that reactivates mutant p53 in cancer cells to finally enhance apoptosis compared to sole carboplatin treatment (Supplementary Fig. 5B, C).